[Role of AGEs-RAGE system in CKD-MBD.]
Journal
Clinical calcium
ISSN: 0917-5857
Titre abrégé: Clin Calcium
Pays: Japan
ID NLM: 9433326
Informations de publication
Date de publication:
Historique:
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
7
8
2019
Statut:
ppublish
Résumé
Abnormalities, such as hyperparathyroidism, vascular calcification, and osteoporosis, are devastating complications in patients with end-stage renal disease(ESRD). These abnormalities significantly affect the quality of life and prognosis. Therefore, controlling the abnormalities of chronic kidney disease-mineral and bone metabolism play an important role in these patients. Conventionally, calcium and phosphorus metabolism abnormalities have been mainly attributed to the development of vascular calcification, but preventing vascular calcification is still difficult even if calcium and phosphorus levels are controlled. Additionally, the mechanisms of the development and progression of vascular calcification in patients with ESRD are still unknown. Recently, advanced glycation end products(AGEs)have been known to be involved in the development and promotion of bone abnormality, such as bone embrittlement and vascular calcification. Therefore, blockade of AGEs and the receptor for AGE(RAGE)system may be a novel therapeutic strategy to improve the prognosis of patients with ESRD by inhibiting bone embrittlement and vascular calcification.
Identifiants
pubmed: 30679400
pii: 1902193198
doi: 10.20837/4201902193
doi:
Types de publication
Journal Article
Langues
jpn